Prime Therapeutics appointed Mostafa Kamal as president of the organization.
Mr. Kamal has been CEO of pharmaceutical benefit manager Magellan Rx since 2015, according to a March 27 news release from Prime Therapeutics. Prime Therapeutics acquired Magellan Rx from Centene in December 2022.
Prime Therapeutics, jointly owned by 19 Blue Cross Blue Shield companies, is integrating the two companies.
Prime CEO Ken Paula will continue in his role, according to the release.